Stem cell research is still too hot for most investors, but NeoStem is starting to change that, thanks to some unexpected events. Among them are the Catholic Church’s surprising embrace of NeoStem’s research and NeoStem’s footh…
French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right that represents potential future payments if Lemtrada, t…
From October 2010 to February 2011, biotech Clinical Data’s stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up — and making it likely to perhaps double again — is speculati…
Just after Genzyme announced that it signed a confidentiality agreement with Sanofi Aventis to allow the French drugmaker to examine its books, leaks about the potential deal started pouring out. The numbers and details vary, s…
Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention — and lots of money…